🔴 Korro Bio is trading 5.1% down today amid a broad biotech selloff and continued fallout from failed drug data

Korro Bio is trading at $12.37 (-5.10%) as it extends a sharp selloff driven by sector-wide weakness and recent negative clinical developments.

• The biotech sector is under significant pressure today, with the SPDR S&P Biotech ETF (XBI) down 2.00% and the Nasdaq trading lower on July 16.
• Shares continue to digest the July 15 announcement regarding failed data for the KRRO-110 RNA-editing program, which resulted in halted development and workforce reductions.
• No new company-specific catalysts were reported for the latest intraday drop, suggesting the move is primarily tied to broader risk-off sentiment across the industry.